Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free BLPH Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Bellerophon Therapeutics (BLPH) Competitors

Bellerophon Therapeutics logo
Compare

BLPH vs. BPTSY, BPTH, VRAX, ONCO, and SRNE

Should you be buying Bellerophon Therapeutics stock or one of its competitors? The main competitors of Bellerophon Therapeutics include Biophytis (BPTSY), Bio-Path (BPTH), Virax Biolabs Group (VRAX), Onconetix (ONCO), and Sorrento Therapeutics (SRNE). These companies are all part of the "pharmaceutical products" industry.

How does Bellerophon Therapeutics compare to Biophytis?

Bellerophon Therapeutics (NASDAQ:BLPH) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, Bellerophon Therapeutics' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
Bellerophon Therapeutics Neutral
Biophytis Neutral

Bellerophon Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500.

10.6% of Bellerophon Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 5.2% of Bellerophon Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biophytis has lower revenue, but higher earnings than Bellerophon Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bellerophon Therapeutics$5.64M0.03-$19.83M-$0.84N/A
BiophytisN/AN/A-$18.43MN/AN/A

Company Net Margins Return on Equity Return on Assets
Bellerophon TherapeuticsN/A N/A N/A
Biophytis N/A N/A N/A

Summary

Bellerophon Therapeutics beats Biophytis on 3 of the 5 factors compared between the two stocks.

How does Bellerophon Therapeutics compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Bellerophon Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Bellerophon Therapeutics N/A N/A N/A

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Bellerophon Therapeutics'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Bellerophon Therapeutics Neutral

Bio-Path has higher earnings, but lower revenue than Bellerophon Therapeutics. Bio-Path is trading at a lower price-to-earnings ratio than Bellerophon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.06N/A
Bellerophon Therapeutics$5.64M0.03-$19.83M-$0.84N/A

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 10.6% of Bellerophon Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 5.2% of Bellerophon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bio-Path has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Summary

Bellerophon Therapeutics beats Bio-Path on 8 of the 9 factors compared between the two stocks.

How does Bellerophon Therapeutics compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Virax Biolabs Group presently has a consensus price target of $1.00, indicating a potential upside of 721.69%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than Bellerophon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bellerophon Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Virax Biolabs Group's average media sentiment score of 0.00 equaled Bellerophon Therapeutics'average media sentiment score.

Company Overall Sentiment
Virax Biolabs Group Neutral
Bellerophon Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
Bellerophon Therapeutics N/A N/A N/A

Virax Biolabs Group has higher earnings, but lower revenue than Bellerophon Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K52.82-$6.06MN/AN/A
Bellerophon Therapeutics$5.64M0.03-$19.83M-$0.84N/A

Virax Biolabs Group has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 10.6% of Bellerophon Therapeutics shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 5.2% of Bellerophon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Virax Biolabs Group beats Bellerophon Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Bellerophon Therapeutics compare to Onconetix?

Onconetix (NASDAQ:ONCO) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Bellerophon Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Onconetix had 1 more articles in the media than Bellerophon Therapeutics. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for Bellerophon Therapeutics. Onconetix's average media sentiment score of 0.00 equaled Bellerophon Therapeutics'average media sentiment score.

Company Overall Sentiment
Onconetix Neutral
Bellerophon Therapeutics Neutral

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 10.6% of Bellerophon Therapeutics shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Comparatively, 5.2% of Bellerophon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Onconetix has higher earnings, but lower revenue than Bellerophon Therapeutics. Bellerophon Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Onconetix$810K0.42-$14.03M-$216.73N/A
Bellerophon Therapeutics$5.64M0.03-$19.83M-$0.84N/A

Onconetix has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Bellerophon Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,717.50%. Onconetix's return on equity of 8.24% beat Bellerophon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Onconetix-1,717.50% 8.24% 2.90%
Bellerophon Therapeutics N/A N/A N/A

Summary

Onconetix beats Bellerophon Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Bellerophon Therapeutics compare to Sorrento Therapeutics?

Sorrento Therapeutics (NASDAQ:SRNE) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 10.6% of Bellerophon Therapeutics shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 5.2% of Bellerophon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bellerophon Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. Bellerophon Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.43N/A
Bellerophon Therapeutics$5.64M0.03-$19.83M-$0.84N/A

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Bellerophon Therapeutics'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Bellerophon Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Bellerophon Therapeutics N/A N/A N/A

Sorrento Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Summary

Bellerophon Therapeutics beats Sorrento Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Bellerophon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLPH vs. The Competition

Export
MetricBellerophon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$147K$889.45M$6.24B$11.86B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio-0.011.7129.0428.48
Price / Sales0.03120.50477.1060.43
Price / CashN/A20.0727.6236.52
Price / Book0.047.609.676.67
Net Income-$19.83M-$4.80M$3.55B$332.64M

Bellerophon Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLPH
Bellerophon Therapeutics
N/A$0.01
flat		N/AN/A$147K$5.64MN/A20
BPTSY
Biophytis
N/A$0.25
flat		N/AN/A$586KN/AN/A30
BPTH
Bio-Path
N/A$0.06
+13.2%		N/AN/A$585KN/AN/A10
VRAX
Virax Biolabs Group
1.7693 of 5 stars		$0.13
-1.6%		$1.00
+658.7%		N/A$572K$2.99KN/A5
ONCO
Onconetix
1.0456 of 5 stars		$0.64
-8.6%		N/AN/A$419K$810KN/A12

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BLPH) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel